Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival. The current trial addresses the relationship between blood and tissue biomarkers, bio-imaging and pathology in patients with early stage NSCLC treated with hypofractionated radiation therapy and surgery.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1
hypofractionated radiation therapy followed by surgery
University Hospital Antwerp
Antwerp, Belgium
University Hospital Ghent
Ghent, Belgium
pathological effects of hypofractionated radiation therapy
To describe the pathological effects of hypofractionated radioation therapy (RT) and to address the relationship with blood and tissue biomarkers and bio-imaging.
Time frame: at 2 years
clinical response rate
Time frame: from 2 to 5 years
the accuracy of clinical mediastinal staging
Time frame: from 2 to 5 years
the complication rate
Time frame: from 2 to 5 years
local, regional or distant failure
Time frame: from 2 to 5 years
progression free survival
Time frame: from 2 to 5 years
disease specific overall survival
Time frame: from 2 to 5 years
overall survival
Time frame: from 2 to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.